Pages that link to "Q81532988"

The following pages link to Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis (Q81532988):

Displaying 41 items.

• A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination (Q28743951) (← links)
• Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination (Q30479247) (← links)
• Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis (Q30530185) (← links)
• Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation (Q30530989) (← links)
• Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway (Q30724821) (← links)
• Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. (Q33735496) (← links)
• Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis (Q34344447) (← links)
• ICAM-1: isoforms and phenotypes (Q34418742) (← links)
• Neuronopathy in the motor neocortex in a chronic model of multiple sclerosis (Q34497257) (← links)
• EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE) (Q34580168) (← links)
• Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis (Q34911293) (← links)
• Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate (Q35008641) (← links)
• Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis (Q35103843) (← links)
• Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica (Q35626822) (← links)
• Inhibition of NADPH oxidase activation reduces EAE-induced white matter damage in mice (Q35668062) (← links)
• Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice (Q35675218) (← links)
• Mechanisms and pharmacology of neuropathic pain in multiple sclerosis (Q35731415) (← links)
• CatWalk gait analysis in a rat model of multiple sclerosis. (Q36208540) (← links)
• The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis (Q36371175) (← links)
• ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE. (Q36629105) (← links)
• Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice (Q36989142) (← links)
• Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis (Q37180260) (← links)
• Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects (Q37210758) (← links)
• Oxidative damage and chemokine production dominate days before immune cell infiltration and EAE disease debut. (Q37258085) (← links)
• Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages. (Q37352125) (← links)
• Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. (Q37401147) (← links)
• Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis (Q37403700) (← links)
• Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus. (Q37681814) (← links)
• Neuroprotective agents: Cannabinoids (Q37855122) (← links)
• The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges. (Q38059361) (← links)
• Connexin43 and connexin47 alterations after neural precursor cells transplantation in experimental autoimmune encephalomyelitis. (Q41011933) (← links)
• A mushroom extract Piwep from Phellinus igniarius ameliorates experimental autoimmune encephalomyelitis by inhibiting immune cell infiltration in the spinal cord (Q41949483) (← links)
• Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis (Q47443833) (← links)
• Sox2 is essential for oligodendroglial proliferation and differentiation during postnatal brain myelination and CNS remyelination. (Q47863799) (← links)
• Behavioral investigation of mice with experimental autoimmune encephalomyelitis (Q50591863) (← links)
• Oxysterol levels and metabolism in the course of neuroinflammation: insights from in vitro and in vivo models. (Q55248842) (← links)
• Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination (Q57457368) (← links)
• Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis (Q64978550) (← links)
• Tocopherol derivative TFA-12 promotes myelin repair in experimental models of multiple sclerosis (Q87075730) (← links)
• Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis (Q92318162) (← links)
• Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model (Q92554650) (← links)